

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



LSHTM Research Online

Baggaley, RF; Owen, BN; Silhol, R; Elmes, J; Anton, P; McGowan, I; van der Straten, A; Shacklett, B; Dang, Q; Swann, EM; +2 more... Bolton, DL; Boily, MC; (2018) Does per-act HIV-1 transmission risk through anal sex vary by gender? An updated systematic review and meta-analysis. American journal of reproductive immunology (New York, NY. e13039. ISSN 1046-7408 DOI: <https://doi.org/10.1111/aji.13039>

Downloaded from: <http://researchonline.lshtm.ac.uk/id/eprint/4649245/>

DOI: <https://doi.org/10.1111/aji.13039>

Usage Guidelines:

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

<https://researchonline.lshtm.ac.uk>

Does per-act HIV-1 transmission risk through anal sex vary by gender? An updated systematic review and meta-analysis

Running title: Meta-analysis of HIV-1 risk of anal sex

Rebecca F Baggaley,^{1,2} Branwen N Owen,¹ Romain Silhol,¹ Jocelyn Elmes,^{1,2} Peter Anton,³ Ian McGowan,⁴ Ariane van der Straten,⁵ Barbara Shacklett,^{6,7} Que Dang,⁸ Edith M Swann,⁸ Diane L Bolton,⁹ Marie-Claude Boily¹

1 Department of Infectious Disease Epidemiology, Imperial College London, London W2 1PG, United Kingdom

2 Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom

3 UCLA Center for HIV Prevention Research, UCLA AIDS Institute, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-7019, United States

4 University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

5 RTI International, Women's Global Health Imperative, San Francisco, CA 94104, United States

6 Department of Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA 95616, United States

7 Division of Infectious Diseases, Department of Medicine, School of Medicine, University of California Davis, Sacramento, CA 95817, United States

8 Vaccine Research Program, Division of AIDS, National Institutes of Health, Bethesda, MD 20892, United States

9 U.S. Military HIV Research Program, The Henry M. Jackson Foundation, Walter Reed Army Institute of Research, Silver Spring, MD 20910, United States

Corresponding author: Rebecca Baggaley, Department of Infectious Disease Epidemiology, St Mary's Campus, Imperial College London, London W2 1PG, United Kingdom. Email: r.baggaley@imperial.ac.uk Tel: +44 (0)20 7594 5777

Word count: 3655

Article type: Review

Conflict of interest statement

We do not have any commercial or other association that might pose a conflict of interest.

Funding

This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health [Grant Number R01AI057020]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the US Army, or the US Department of Defense. We thank the HPTN Modelling Centre, which is funded by the U.S. National Institutes of Health (NIH UM1 AI068617) through HPTN, for partial funding of this work.

Abstract

Quantifying HIV-1 transmission risk per act of anal intercourse (AI) is important for HIV-1 prevention. We updated previous reviews by searching Medline and Embase to 02/2018. We derived pooled estimates of receptive AI (URAI) and insertive AI (UIAI) risk unprotected by condoms using random effects models. Subgroup analyses were conducted by gender, study design, and whether antiretroviral treatment (ART) had been introduced by the time of the study.

Two new relevant studies were identified, one of which met inclusion criteria, adding three new cohorts and increasing number of individuals/partnerships included from 1869 to 14,277. Four studies, all from high-income countries, were included. Pooled HIV-1 risk was higher for URAI (1.25%, 95%CI 0.55-2.23%, $N=5$, $I^2=87\%$) than UIAI (0.17%, 95%CI 0.09-0.26%, $N=3$, $I^2=0\%$). The sole heterosexual URAI estimate (3.38%, 95%CI 1.85-4.91%), from a study of 72 women published in a peer-reviewed journal, was significantly higher than the MSM pooled estimate (0.75%, 95%CI 0.56-0.98%, $N=4$, $p<0.0001$) and higher than the only other heterosexual estimate identified (0.4%, 95%CI 0.08-2.0%, based on 59 women, excluded for being a pre-2013 abstract). Pooled per-act URAI risk varied by study design (retrospective-partner studies: 2.56%, 95%CI 1.20-4.42%, $N=2$ (one MSM, one heterosexual); prospective studies: 0.71%, 95%CI 0.51-0.93%, $N=3$ MSM, $p<0.0001$). URAI risk was lower for studies conducted in the ART era (0.75%, 95%CI 0.52-1.03%) than pre-ART (1.67%, 95%CI 0.44-3.67%) but not significantly so ($p=0.537$).

Prevention messages must emphasise that HIV-1 infectiousness through AI remains high, even in the ART era. Further studies, particularly among heterosexual populations and in resource-limited settings, are required to elucidate whether AI risk differs by gender, region and following population-level ART scale-up.

Keywords: HIV, anal intercourse, transmission probability, infectivity, review, meta-analysis, heterosexual, MSM, antiretroviral therapy

Introduction

Anal intercourse (AI) drives HIV-1 epidemics among men-who-have-sex-with-men (MSM), and numerous studies have demonstrated that substantial proportions of heterosexual populations also practise AI^{1, 2}, potentially making it an important source of heterosexual HIV-1 transmission³. Quantifying the role of AI in HIV-1 epidemics is important for effective targeting of safe sex messages, for developing and implementing HIV-1 prevention technologies, and to inform mathematical models. Two previously published systematic reviews and meta-analyses have only included four studies providing estimates of the probability of HIV-1 transmission per AI act unprotected by condoms^{4, 5}.

Baggaley et al derived the first pooled receptive AI unprotected by condoms (URAI) per-act estimates in 2010 (1.37%, 95% confidence interval[95%CI] 0.20-2.54%)⁵. Patel et al⁴ updated the review to February 2012, and derived a similar pooled estimate to Baggaley et al despite excluding a study included in Baggaley et al⁶ and incorporating one new study (1.38%, 95%CI 1.02-1.86%)^{5, 7}. Patel also reported a pooled estimate for insertive AI unprotected by condoms (UIAI): 0.1% (95%CI 0.0-0.3%). However, since their search, additional per-act estimates derived from large HIV-1 cohort datasets have been published^{8, 9}. Given the scarce data on per-act AI HIV risk, it is important to update pooled estimates in light of new data, to reduce uncertainty and provide more reliable estimates to address public health questions and for use in models.

Addition of further data may enable evaluation of how HIV-1 infectiousness through AI varies by gender of participants, by ART use in the general population, region and other study characteristics. For example, recent evidence from animal studies suggests increased susceptibility of male rhesus macaques to HIV-1 acquisition following intrarectal challenge, compared to females (Diane Bolton, personal communication).

Our aim was to revise pooled estimates of URAI and insertive AI unprotected by condoms (UIAI) per-act HIV-1 transmission risk through incorporation of new data. We aimed to assess whether the

addition of new data leads to significantly different pooled estimates of AI per-act risk; to evaluate the robustness of pooled estimates through sensitivity analysis; and to conduct subgroup analysis to investigate the influence of: 1) ART use among study participants or their partners; 2) gender; 3) region; and 4) study design.

Methods

The systematic review and meta-analysis were conducted in accordance with the PRISMA statement¹⁰.

Search strategy

We conducted literature searches to identify new studies reporting data on per-act HIV-1 transmission risk through anal intercourse (AI) published since searches originally performed by Baggaley et al⁵ (searched to September 2008), and Patel et al⁴ (searched to February 2012). Our search was harmonised to ensure inclusion of terms employed previously^{4, 5}. We used the following search string: (HIV OR HIV infections OR human immunodeficiency virus OR AIDS) AND (disease transmission OR infectious OR infectivity OR infectiousness OR transmissibility OR contact OR contacts OR per-contact OR per-act OR effectiveness) AND (sexual OR heterosexual OR homosexual OR coital OR intercourse OR anal). We searched Medline (Ovid), Embase (Ovid), CINAHL (EbscoHost), Web of Science, Global Health, and the Cochrane Library for studies published February 2012 to February 2018 inclusive. See Supplementary Material for further search details.

Unlike Baggaley et al⁵, which focused on transmission risk estimates in the absence of ART, we also included studies where ART was likely used by a proportion of study participant partners. This change of inclusion criterion necessitated searching the exclusion lists of Baggaley et al⁵ to ensure no studies were excluded based on ART use. We defined ART use to include therapeutic use by index

(i.e. initially infected) partners, or pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) use by their (initially uninfected) partners.

Study selection

Inclusion criteria were randomised controlled trials, longitudinal studies (prospective or retrospective) or other empirical observational studies that directly reported estimates of per-act HIV-1 transmission risk through AI. We excluded studies that did not stratify AI risk, receptive versus insertive. Abstracts pre-2013, studies using sample sizes less than 10, and estimates derived from dynamic transmission modelling studies fitted to empirical HIV-1 prevalence curves, were excluded. While we included studies where study populations included individuals using ART, we aimed to include “real life studies” only, and so excluded studies where successful, suppressive ART of index partners was an inclusion criterion. Abstracts and other unpublished data older than five years were excluded because they were unlikely to result in peer-reviewed publication. There was no restriction by study year, region, or language of publication. AI per-act estimates included in previous systematic reviews^{4, 5}, which we refer to as “original estimates”, were included if they fulfilled the current inclusion criteria.

Data extraction

Study review was conducted independently by two separate authors (RFB and BNO). Data were extracted on the following study and participant characteristics: region, study design, study dates, gender (MSM or heterosexual study population), sample size, statistical method of estimating per-act risk, information on current and history of sexually transmitted infections (STIs), proportion of the study partner population using therapeutic ART and stage of HIV-1 infection of infected partners, condom use, intravenous drug use and ART use (PrEP or PEP). Discrepancies were resolved by consensus.

Statistical methods

We performed random-effects inverse-variance meta-analysis¹¹ on arcsin-transformed study estimates, which were back-transformed to the original scale to produce pooled estimates for per-act risk of HIV-1 transmission through URAI and UIAI. We presented available study estimates and pooled URAI and UIAI estimates in forest plots.

Meta-regression and subgroup analysis were used to explore potential sources of heterogeneity: gender; study design e.g. retrospective-partner study, prospective cohort of individuals; and ART use among partners. We assessed the robustness of pooled estimates and the influence of each individual study using leave-one-out sensitivity analysis (i.e., an influence analysis¹¹). We also assessed the influence of relaxing our inclusion criteria to include Halperin et al (0.4%, 95%CI 0.08-2.0%, excluded for being unpublished data pre-2013⁶). Heterogeneity across study estimates was assessed using I^2 statistics. Analysis was performed using R version 3.4.2¹² and the metafor package.

Results

Search results

Of 5336 unique studies published from February 2012 to February 2018 that we identified in our online searches, 4985 were excluded for non-relevance based on title, and 349 excluded based on abstract or full text. Two new articles directly reported per-act HIV-1 transmission probability estimates^{8,9}. No study had been excluded from our previous review based on ART use. Figure 1 illustrates the study selection procedure.

Studies included in each systematic review

Table 1 summarises per-act URAI and UIAI transmission risk estimates and study characteristics for estimates included in Baggaley et al 2010⁵, Patel et al⁴ and the current analysis. Detailed study characteristics are shown in Table S1, Supplementary Material. Data from 14,227 and 14,000 individuals/partnerships reported in the included studies were used to inform URAI and UIAI pooled estimates, respectively, compared to 1869 individuals/partnerships included in Baggaley et al⁵).

Of the two newly-identified studies^{8,9}, Scott et al⁸ was preferentially included. Smith et al⁹ used data from EXPLORE¹³ and VAX 004¹⁴ studies, while Scott et al⁸ additionally included Jumpstart¹⁵ and HIVNET Vaccine Preparedness Study (VPS)^{16, 17} data. Furthermore, Smith et al⁹ did not account for risk factors such as ethnicity and drug use, or for heterogeneity in per-act risk, as Scott did. Scott et al⁸ results also superseded and improved upon Vittinghoff et al¹⁸ estimates, which were conducted by the same research group and included the same Jumpstart study data. Vittinghoff et al¹⁸ data are therefore excluded. Halperin et al⁶, included by Baggaley et al⁵, was excluded for being a pre-2013 abstract. Further details of the advantages of Scott et al methodology, together with further information regarding excluded studies, are provided in Supplementary Material.

Study characteristics

Five URAI per-act study estimates reported by four studies^{7, 8, 19, 20} and three UIAI estimates reported by two studies^{7, 8} were included in the current analysis (Figure 1). Scott et al⁸ provided independent estimates for pre-highly active antiretroviral therapy (HAART, hereafter referred to as ART: study data from 1992-1995) and early ART (study data from 1995-2003) eras, for both URAI and UIAI, because they combined data from four cohorts¹³⁻¹⁷.

Data collection occurred between 1987 and 2007, although the earliest included publication did not state study dates¹⁹. URAI study estimates used data from Australia (N=1⁷), the US (N=3^{8, 19}) and one multi-European country study²⁰ (Table 1). UIAI study estimates used data from Australia (N=1⁷) and the US (N=2¹⁹). All but one included study estimate (Leynaert et al²⁰, URAI) used data from MSM populations (Figure 2). Two URAI study estimates were from retrospective-partner studies^{19, 20}; the remaining three used data from prospective cohorts of individuals^{7, 8}.

Three URAI study estimates used face-to-face interview (FTFI) data (^{8, 20} and pre-ART¹⁹), a third used FTFI combined with telephone interviewing⁷, and Scott et al's⁸ early ART study estimate combined data gathered using FTFI (VAX004¹⁴ and VPS^{16, 17}) and audio computer-assisted self-interview (ACASI) (Explore¹³). For UIAI, all three study estimates were from prospective studies and data were

collected using FTFI (pre-ART¹⁹), FTFI plus telephone interview⁷ and FTFI plus ACASI combined (early ART⁸).

No studies reported on ART use of index partners. These data were not available from cohorts of individuals because they cannot be collected using this design^{7, 8}. Authors discussed plausible ART coverage among infected partners but did not attempt to adjust estimates to account for ART use. Jin et al cited national data that 70% of Australian MSM used ART, and 75% of those had undetectable viral load⁷. For their early ART era estimates, Scott et al cited national data that only around 80% of those infected were aware of their status, and only 30% were virally suppressed, and that these levels were probably even lower during study periods. ART use was also not collected by retrospective-partner studies^{19, 20}. Leynaert et al (retrospective-partner) reported that ART use data were not collected, but the study was conducted 1987-1992 and so use was minimal²⁰. Similarly, DeGruttola et al (retrospective-partner) was published in 1989¹⁹. Therefore ART use was minimal, likely 0%, in 3 of 5 (^{19, 20} and pre-ART⁸) and 1 (pre-ART⁸) of 3 URAI and UIAI study estimates, respectively. The remaining two studies were classed as having >0% ART use^{7, 8}. Although no included studies reported any information on PEP or PrEP use by study participants, its use is expected to be very low, given the dates of data collection (all before 2007).

Study size varied considerably. Retrospective-partner studies enrolled 155¹⁹ and 72²⁰ couples, while cohorts followed between 1427⁷ and 4581 (EXPLORE¹³, included as part of Scott et al⁸) individuals. Number of AI acts with a partner appeared to vary considerably between individuals in the same study, with infectiousness similarly heterogeneous: Jin et al noted that 12 seroconversions in their cohort occurred as a result of <10 unprotected AI acts, while six men did not seroconvert despite reporting a total of 502 URAI acts with ejaculation⁷. Similarly, DeGruttola reported that 12 men reported >100 URAI acts with HIV-1-infected partners without seroconverting, while five men seroconverted after ≤10 such exposures to their infected partner and <3 partners outside the main relationship¹⁹.

Meta-analysis results

The updated pooled estimate of per-act URAI HIV-1 risk of 1.25% (95%CI 0.55-2.23%, $N=5$, $I^2=87\%$)^{7, 8, 19, 20}) was considerably and statistically significantly higher ($p=0.0026$) and more heterogeneous than the UIAI risk (0.17%, 95%CI 0.09-0.26%, $I^2=0\%$, $N=3$ ^{7, 8}). Pooled and study estimates are shown in Figure 2.

Subgroup analysis

Table 2 shows the results of the subgroup analysis. The pooled per-act URAI HIV-1 risk was significantly lower for MSM (0.75% 95%CI 0.56-0.98%, $N=4$) than the sole heterosexual population estimate (3.38% 95%CI 1.85-4.91%, $N=1$) ($p<0.0001$). However, relaxing inclusion criteria to include Halperin et al⁶ (0.4% 95%CI 0.08-2.0%), one of just two identified estimates from heterosexual populations, excluded for being an abstract pre-2013, reduced the pooled heterosexual URAI estimate to 1.57% (95%CI 0.00-5.87%, $N=2$, $I^2=91\%$) which was no longer significantly different from the MSM estimate ($p=0.370$, Figure S1). MSM per-act estimates for both URAI and UIAI showed relatively little heterogeneity ($I^2<0.1\%$).

Pooled per-act URAI risk from studies where ART was likely to have been used by >0% of sexual partners was lower than half (0.75%,95%CI 0.52-1.03%, $N=2$) that without ART use (1.67%,95%CI 0.44-3.67%, $N=3$) but this difference was not significant ($p=0.537$). Per-act UIAI risks were similar by ART use (0.14%,95%CI 0.04-0.29% for 0% use vs. 0.18%,95%CI 0.09-0.31% for >0% use, $p=0.955$). When assessed in multivariate meta-regression analysis, only study design was (borderline) significantly associated with magnitude of URAI transmission risk ($p=0.055$), accounting for >99% of the heterogeneity across study estimates ($R^2=99.9\%$). Meta-regression analysis could not be undertaken for UIAI given the small number of estimates ($N=3$, all from MSM populations).

Sensitivity analysis

In the leave-one-out sensitivity analysis, only the omission of the heterosexual URAI estimate from Leynaert et al²⁰ among heterosexual couples substantially reduced heterogeneity (I^2 reduced from 87% to 0%), producing an all-MSM pooled URAI estimate (0.75%, 95%CI 0.56-0.98%) (Figure S1). Adding the Halperin et al⁶ study estimate did not substantially influence the URAI pooled estimate (1.10%, 95%CI 0.50-1.94%, $I^2=85\%$, Figure S1). The pooled UIAI estimate was also not affected by any individual study estimate because study estimates were remarkably homogeneous (Figure 2, $I^2=0$).

Discussion

Our updated review incorporates recently-published study estimates which strengthen the analysis and robustness of pooled per-act risk estimates by greatly increasing the number of included individuals (data from 14,227 individuals/partnerships, compared to 1869 individuals/partnerships in Baggaley et al⁵). Our results highlight that risk of HIV-1 transmission through AI remains high (1.25%, 95%CI 0.55-2.23%, $N=5$ for URAI; 0.17%, 95%CI 0.09-0.26%, $N=3$ for UIAI), and raises the question of whether HIV risk during URAI is higher for women than MSM, also highlighting the lack of data from resource-limited settings.

Our new pooled estimate is slightly lower than the previous pooled URAI estimates by Baggaley et al⁵ and Patel et al⁴, and a slight, nonsignificant increase on the previous pooled UIAI estimate reported by Patel et al⁴. We have explored sources of heterogeneity as far as possible, given the few included study estimates. In fact, URAI and UIAI estimates from MSM study populations were remarkably homogeneous ($I^2=0\%$). It is unclear whether gender or study design accounted for the heterogeneity across all URAI study estimates, but even after omitting the highest URAI estimate (i.e., the sole heterosexual estimate²⁰, see Figure S1), the estimate of HIV-1 transmission risk through URAI remained high (0.75%, 95%CI 0.56-0.98%). Even considering only study estimates which were conducted since the introduction of ART, risk remained nearly 10-fold riskier than unprotected

receptive vaginal intercourse (VI): URAI 0.75%,95%CI 0.52-1.03% vs. unprotected receptive VI: 0.08%,95%CI 0.06-0.11%²¹. UIAI risk in the ART era is more than four-fold riskier than insertive VI (0.18%,95%CI 0.09-0.31% vs. 0.04%,95%CI 0.01-0.14%²¹).

It is unclear why the Leynaert et al URAI risk among females was so high (3.38%, 95%CI 1.85-4.91%²⁰). All studies were conducted in industrialised countries, so difference by region is unlikely. Heterosexual study participants reported monogamy and no STIs. However, a large proportion of index cases (65% of the entire sample) were infected by intravenous drug use, so while their sexual partners reported no such use, it is possible that they underreported HIV-1 exposure and acquired HIV-1 via this route. Leynaert et al was a retrospective-partner study, and in multivariate meta-regression, study design explained a larger fraction of the variation across URAI estimates than gender, so the apparent difference by gender may be confounded by study design. HIV risk during URAI is especially uncertain because the only other identified URAI estimate among females, which was excluded for being a pre-2013 abstract, provided a markedly lower estimate than Leynaert et al (0.4% 95%CI 0.08-2.0%): it is in fact lower than all the five included URAI study estimates. This clouds the picture of potential differential risk by gender. The sample sizes of both Leynaert and Halperin were low (n<80), and given heterogeneity in infectiousness between individuals and by stage of HIV-1 infection²⁵, the widely different estimates may be due to chance (95%CI are wide and overlapping: 1.85-4.91%²⁰ and 0.08-2.0%⁶). The lack of study design detail for the Halperin abstract makes it difficult to postulate reasons for the low estimate. However, our main results, based on the a priori exclusion of Halperin et al, mean we cannot exclude the possibility that women have an intrinsically higher URAI HIV-1 acquisition risk than men. This warrants further research, given its implication for HIV-1 prevention. There may exist underlying biological differences between the rectal compartments of males and females, rendering women more susceptible to infection. For example, there may be sex hormone differences, which alter rectal mucosal immunology and enhance susceptibility²⁶. However, there has been little research conducted in this area to date, and recent evidence from animal studies suggested an opposite effect (Diane Bolton, person

communication). Alternatively, variation in sexual practices by gender may play a role. MSM may be more likely to anticipate receptive AI and therefore prepare to reduce the likelihood of trauma (such as use of lubricants, cleansing the colon). Qualitative research has suggested that heterosexual AI often occurs without the explicit prior consent of women^{27, 28}.

Our meta-regression found the pooled URAI risk among studies conducted in the ART era, when there was likely to be >0% ART use among sexual partners of study participants, was less than half that from pre-ART studies, but this difference failed to reach statistical significance, probably partly because of the small number of estimates and also the variability across estimates in the pre-ART era (from 0.60%⁸ to 3.38%²⁰). For both URAI and UIAI, Scott et al pre-ART and early ART era per-act study estimates were very similar. Scott et al explained this lack of a significant association by suggesting that a relatively low proportion of infected MSM were on ART and had a suppressed viral load during the years in which data were collected. However, Jin et al⁷ URAI estimates were also high, and similar to Baggeley et al⁵ 2010's pooled estimate (without ART use), despite the likely high ART use in the Australian study population. In fact, omitting the high heterosexual URAI estimate from Leynaert et al²⁰ makes pre-ART and ART era URAI estimates more comparable: 1.00% (95%CI 0.22-2.33%) and 0.75% (95%CI 0.52-1.03%), respectively.

However, as Jin and Scott et al followed individuals rather than couples over time, information on infection status, current ART use and viral load of each sexual partner of each study participant was missing: data that are required to control for ART use adequately. While evidence shows that HIV-infected individuals with ART-mediated viral suppression do not transmit HIV-1²²⁻²⁴, our findings demonstrate that HIV-1 infectiousness through AI remains high, indicating that many HIV-infected individuals practising condomless AI are not on effective ART and remain infectious.

With ART coverage having continued to increase, now taken at earlier stages of HIV-1 infection and more tolerable regimens increasing levels of adherence, and with the advent of PrEP, it is expected that any

future AI HIV-1 infectiousness studies would find further, significant reductions in infectiousness estimates. However, HIV-infected MSM engaging in nondisclosing (not disclosing their HIV status to their partner), condomless AI have been found to be less ART-adherent and more likely to have unsuppressed HIV³¹ and so it is important to collect further data to monitor whether these population-level AI HIV-1 infectiousness estimates continue to decline over time.

There are some limitations to our findings, mainly due to scarcity of data. The few study estimates prevent us exploring the sources of heterogeneity in greater depth. Only one heterosexual study estimate was included, so it is difficult to know if differences in infectiousness by gender are real or confounded by study design. Included estimates were from only two study types: retrospective-partner and prospective studies of individuals. Both have advantages and disadvantages. For example, prospective studies are less likely to experience recall bias and therefore estimating numbers of sex acts may be more precise than retrospective studies. Recruiting individuals is easier than recruiting couples, providing larger sample sizes. Partner studies provide more reliable data on index cases, particularly regarding HIV-1 status, and in theory on their patterns of ART use. Studies of individuals rely on participants' perceptions of the status of their sexual partners. However, couples may be more likely to underreport sexual partners outside the main relationship because of social desirability bias. Leynaert et al only reported from monogamous couples²⁰, but all other study estimates included participants reporting multiple partners and multiple sexual behaviours. It can be challenging to estimate transmission risks using such data, especially where the HIV-1 infection and ART use status of sexual partners cannot be known with certainty: there are a lot of unknowns which must be accounted for. Different studies have used different statistical techniques to attempt this. All but one study used FTFI to gather sexual behaviour data, which may lead to social desirability bias³². These limitations may over- or underestimate per-act risk, and together with the small number of studies identified, and the variation in methods of data analysis, mean we recommend further data gathering using more confidential techniques such as ACASI, and analysis using standardised statistical methods, to increase comparability of studies and robustness of pooled

295 estimates. Publication bias and selective reporting are likely to be low, because these studies are not
296 assessing significance or effectiveness outcomes. This bias could be investigated using funnel plots if
297 more study estimates became available.

298 In conclusion, current evidence suggests that practising unprotected AI continues to confer a high
299 risk of HIV-1 transmission, particularly URAI, even in the ART era. More research is needed as
300 important knowledge gaps regarding HIV-1 risk during AI remain. Given the high HIV-1 transmission
301 risk associated with AI, it is remarkable that more research has not been conducted to evaluate if AI
302 transmissibility differs by gender, high- and low-income countries and following ART scale-up at the
303 population level. Standardised methods should be used to aid comparability between studies, and
304 longitudinal studies reporting HIV transmission rates should be encouraged to use these methods to
305 additionally report per-act estimates. Even today it continues to be important to design safe sex
306 messaging that promotes the use of condoms in addition to interventions such as PrEP and other
307 biotechnologies to prevent HIV-1 transmission through AI for both MSM and heterosexual
308 populations.

References

1. Owen, B.N., et al., *Prevalence and Frequency of Heterosexual Anal Intercourse Among Young People: A Systematic Review and Meta-analysis*. AIDS Behav, 2015. **19**(7): p. 1338-60.
2. Owen, B.N., et al., *How common and frequent is heterosexual anal intercourse among South Africans? A systematic review and meta-analysis*. J Int AIDS Soc, 2017. **19**(1): p. 21162.
3. Maheu-Giroux, M., et al., *Anal Intercourse Among Female Sex Workers in Cote d'Ivoire: Prevalence, Determinants, and Model-Based Estimates of the Population-Level Impact on HIV Transmission*. Am J Epidemiol, 2018. **187**(2): p. 287-297.
4. Patel, P., et al., *Estimating per-act HIV transmission risk: a systematic review*. AIDS, 2014. **28**(10): p. 1509-19.
5. Baggaley, R.F., R.G. White, and M.C. Boily, *HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention*. Int J Epidemiol, 2010. **39**(4): p. 1048-63.
6. Halperin, D.T., et al., *High level of HIV-1 infection from anal intercourse: a neglected risk factor in heterosexual AIDS prevention*. Abstract ThPeC7438. International Conference on AIDS 2002, July 7-12. 2002.
7. Jin, F., et al., *Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART*. AIDS, 2010. **24**(6): p. 907-13.
8. Scott, H.M., et al., *Age, race/ethnicity, and behavioral risk factors associated with per contact risk of HIV infection among men who have sex with men in the United States*. J Acquir Immune Defic Syndr, 2014. **65**(1): p. 115-21.
9. Smith, D.K., et al., *Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States*. J Acquir Immune Defic Syndr, 2015. **68**(3): p. 337-44.
10. Moher, D., et al., *Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement*. Int J Surg, 2010. **8**(5): p. 336-41.
11. Deeks, J.J., D.G. Altman, and M.J. Bradburn, *Chapter 15: Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis*. In: *Systematic review in health care: Meta-analysis in context*. BMJ Books, London, U.K. 1995.
12. R Core Team (2012). *R: A language and environment for statistical computing*. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL <http://http://www.R-project.org/>.
13. Koblin, B., et al., *Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study*. Lancet, 2004. **364**(9428): p. 41-50.
14. Bartholow, B.N., et al., *Demographic and behavioral contextual risk groups among men who have sex with men participating in a phase 3 HIV vaccine efficacy trial: implications for HIV prevention and behavioral/biomedical intervention trials*. J Acquir Immune Defic Syndr, 2006. **43**(5): p. 594-602.
15. Buchbinder, S.P., et al., *Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate*. J Infect Dis, 1996. **174**(5): p. 954-61.
16. Flynn, N.M., et al., *Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection*. J Infect Dis, 2005. **191**(5): p. 654-65.
17. Seage, G.R., 3rd, et al., *Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study*. Am J Epidemiol, 2001. **153**(7): p. 619-27.
18. Vittinghoff, E., et al., *Per-contact risk of human immunodeficiency virus transmission between male sexual partners*. Am J Epidemiol, 1999. **150**(3): p. 306-11.

19. DeGruttola, V., et al., *Infectiousness of HIV between male homosexual partners*. J Clin Epidemiol, 1989. **42**(9): p. 849-56.
20. Leynaert, B., A.M. Downs, and I. de Vincenzi, *Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection*. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol, 1998. **148**(1): p. 88-96.
21. Boily, M.C., et al., *Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies*. Lancet Infect Dis, 2009. **9**(2): p. 118-29.
22. Cohen, M.S., et al., *Antiretroviral Therapy for the Prevention of HIV-1 Transmission*. N Engl J Med, 2016. **375**(9): p. 830-9.
23. Baggaley, R.F., et al., *Heterosexual HIV-1 infectiousness and antiretroviral use: systematic review of prospective studies of discordant couples*. Epidemiology, 2013. **24**(1): p. 110-21.
24. Bavinton, B.R., et al., *Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study*. Lancet HIV, 2018.
25. Boily, M.C., R.F. Baggaley, and B. Masse, *The role of heterosexual anal intercourse for HIV transmission in developing countries: are we ready to draw conclusions?* Sex Transm Infect, 2009. **85**(6): p. 408-10.
26. McGowan, I., et al., *A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007)*. PLoS One, 2013. **8**(4): p. e60147.
27. Marston, C. and R. Lewis, *Anal heterosex among young people and implications for health promotion: a qualitative study in the UK*. BMJ Open, 2014. **4**(8): p. e004996.
28. Reynolds, G.L., D.G. Fisher, and B. Rogala, *Why women engage in anal intercourse: results from a qualitative study*. Arch Sex Behav, 2015. **44**(4): p. 983-95.
29. Rodger, A.J., et al., *Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy*. JAMA, 2016. **316**(2): p. 171-81.
30. Powers, K.A., et al., *Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis*. Lancet Infect Dis, 2008. **8**(9): p. 553-63.
31. Kalichman, S.C., et al., *HIV Disclosure and Transmission Risks to Sex Partners Among HIV-Positive Men*. AIDS Patient Care STDS, 2016. **30**(5): p. 221-8.
32. Langhaug, L.F., L. Sherr, and F.M. Cowan, *How to improve the validity of sexual behaviour reporting: systematic review of questionnaire delivery modes in developing countries*. Trop Med Int Health, 2010. **15**(3): p. 362-81.
33. Higgins, J.P., et al., *Measuring inconsistency in meta-analyses*. BMJ, 2003. **327**(7414): p. 557-60.

Tables

Table 1 Summary of per-act anal intercourse HIV-1 transmission probability studies included in meta-analyses reported by Baggaley et al 2010⁵, Patel et al⁴, and the current analysis. Reasons for study exclusion are provided, where applicable.

Study	Population, sample size, setting	Design. Study dates	Per-act estimate, % (95%CI)	Included in:		
				Baggaley et al 2010	Patel et al 2014	Current analysis
URAI						
DeGruttola et al 1989 ¹⁹	132 MSM (some infected, some uninfected) plus 155 sexual partners, US	Retrospective-partner, study dates not stated	0.5-3.0 ^a	✓	✓	✓
Leynaert et al 1998 ²⁰	72heterosexual couples (male index) practising AI, Europe	Retrospective-partner, 1987-1992	3.38 (1.85-4.91)	✓	✓	✓
Vittinghoff et al 1999 ¹⁸	1583 MSM, US	Prospective cohort of individuals, 1992-1994	0.82 (0.24-2.76)	✓	✓	✗ Superseded ^c
Halperin et al 2002 (abstract) ⁶ plus S.C. Shiboski (personal communication, 2003)	59 heterosexual couples (male index), US	Retrospective-partner, participants recruited 1985-1986	0.4 (0.08-2.0) ^b	✓	✗ Estimate interpreted as a relative risk	✗ Abstract pre-2013
Jin et al 2010 ⁷	1427 MSM, Australia	Prospective cohort of individuals, 2001-2007	0.91 ^d (0.41-2.07)	✗ Data not yet published	✓	✓

Study	Population, sample	Design. Study dates	Per-act estimate, %		Included in:		
	size, setting				(95%CI)	Baggaley et al 2010	Patel et al 2014
Scott et al 2014 ⁸	MSM, US	Four prospective cohorts			x	x	✓
	Pre-ART N=1813 ^c	of individuals: Jumpstart	0.60 ^e	(0.34-1.09)	Data not yet published	Not included ⁹	
	Early ART N=10,760 ^f	1992-1995 ¹⁵ , EXPLORE	0.73 ^f	(0.45-0.98)			
		1999-2003 ¹³ , VAX 004					
		1998-2002 ¹⁴ , VPS 1995-1999 ^{16, 17}					
Smith et al 2015 ⁹	3490 MSM, US	Two prospective cohorts	1.11 ^h	(0.75-1.62)	x	x	x
		of individuals: EXPLORE	0.41 ⁱ	(0.30-0.55)	Data not yet published	Data not yet published	Study data reported by
		1999-2003 ¹³ , VAX 004					Scott et al 2014 ⁸
		1998-2002 ¹⁴					
UIAI							
Vittinghoff et al 1999 ¹⁸	1583 MSM, US	Prospective cohort of individuals, 1992-1994	0.06	(0.02-0.19)	x	✓	x
					Estimate is per partner of HIV-1 positive or unknown serostatus		Estimate is per partner of HIV-1 positive or unknown serostatus; superseded ^c
Jin et al 2010 ⁷	1427 MSM, Australia	Prospective cohort of individuals, 2001-2007	0.16	(0.05-0.31)	x	✓	✓
					Data not yet published		

Study	Population, sample size, setting	Design. Study dates	Per-act estimate, % (95%CI)		Included in:		
					Baggaley et al 2010	Patel et al 2014	Current analysis
Scott et al 2014 ⁸	MSM, US	Four prospective cohorts			x	x	✓
	Pre-ART N=1813 ^c	of individuals: Jumpstart	0.14 ^e	(0.04-0.29)	Data not yet published	Not included ^g	
	Early ART N=10,760 ^f	1992-1995 ¹⁵ , EXPLORE	0.22 ^f	(0.05-0.39)			
		1999-2003 ¹³ , VAX 004 1998-2002 ¹⁴ , VPS 1995- 1999 ^{16, 17}					
Smith et al 2015 ⁹	3490 MSM, US	Two prospective cohorts	0.27 ^h	(0.18-0.41)	x	x	x
		of individuals: EXPLORE	0.20 ⁱ	(0.15-0.27)	Data not yet published	Data not yet published	Study data reported by Scott et al 2014 ⁸
		1999-2003 ¹³ , VAX 004 1998-2002 ¹⁴					

NS – not stated.

^a Range rather than 95%CI reported by publication.

^b Range rather than 95%CI.

^c Estimate superseded by reanalysis of the dataset reported in Scott et al 2014⁸.

^d Jin et al⁷ published per-act risk with ejaculation taking place inside the rectum (1.43%, 95%CI 0.48-2.85%) and with withdrawal prior to ejaculation (0.65%, 95%CI 0.15-1.53%). Per-act estimate regardless of when ejaculation occurred was reported in Patel et al⁴, obtained from study authors (James Jansson, personal communication).

^e Data taken from the pre-ART era (estimates use data from the Jumpstart study¹⁵).

^f Data taken from the early ART era (estimates use data from the EXPLORE¹³, VAX 004¹⁴, and VPS^{16, 17} studies).

^g Data mentioned in text but not included in meta-analysis

^h Data taken from the EXPLORE study¹³, restricted to study participants reporting never using condoms.

ⁱ Data taken from the VAX 004 study¹⁴, restricted to study participants reporting never using condoms.

Table 2 Subgroup analysis: meta-analytic pooled per-act HIV-1 transmission probability estimates for URAI and UIAI stratified by population subgroup (heterosexual and MSM), study design (retrospective-partner and prospective cohort of individuals) and plausible extent of ART use by sexual partners (0% versus >0%).

Estimate type	Pooled estimate, % (95%CI)	P ^a	I ^{2,b} , (%)	N	References	p-value ^a
URAI						
Gender						
Women	3.38 (1.85-4.91)	1.000	0.0%	1	20	p<0.0001
MSM	0.75 (0.56-0.98)	0.278	<0.1%	4	7, 8, 19c	
Study design						
Retrospective-partner	2.56 (1.20-4.42)	0.1296	56.5%	2	19, 20	p<0.0001
Prospective cohort of individuals	0.71 (0.51-0.93)	0.722	0.0%	3	7, 8c	
Plausible extent of ART use by sexual partners						
0%	1.67 (0.44-3.67)	<0.0001	87.6%	3	8, 19, 20d	p=0.537
>0%	0.75 (0.52-1.03)	0.650	0.0%	2	7, 8d	
Pooled estimate	1.25 (0.55-2.23)	0.0002	87.3%	5	7, 8, 19, 20c	
UIAI ^e						
Plausible extent of ART use by sexual partners						
0%	0.14 (0.04-0.29)	1.000	0.0%	1	8	P=0.955
>0%	0.18 (0.09-0.31)	0.604	0.0%	2	7, 8c	
Pooled estimate	0.17 (0.09-0.26)	0.7716	0.0%	3	7, 8c	

ART – antiretroviral treatment; N – number of study estimates; NA – not applicable; P – P-value; Q – heterogeneity statistic; UIAI – unprotected insertive anal intercourse; URAI – unprotected receptive anal intercourse.

^a “P” is the p-value for heterogeneity of the pooled estimate; “p-value” is the metaregression p-value defining the significance of the difference in pooled estimates between the two subgroups.

^b I² is calculated as described in Higgins et al³³. I² lies between 0 and 100%; 0% indicates no observed heterogeneity and larger values show increasing heterogeneity.

^c Two URAI and UIAI estimates were provided by Scott et al⁸, using data from studies conducted in the pre-ART and early ART eras.

^d Scott et al's⁸ pre-ART estimates are classed as likely 0% ART use; its early ART estimates are classed as >0% use.

^e All UIAI study estimates used data from prospective cohorts of individuals from MSM populations and so subgroup analysis could not be conducted gender or design.

Figure legends

Figure 1 Flowchart summary of the literature search, comprising an update search from 2012 to February 2018 and a catch-up search to ensure the pre-2012 search included the same search terms as the updated search. “Original estimates” refers to studies included in either previous review^{4, 5}.

ART – antiretroviral therapy; CINAHL – Cumulative Index to Nursing and Allied Health Literature; UIAI – unprotected insertive anal intercourse; URAI – unprotected receptive anal intercourse.

Figure 2 Forest plot of studies estimating per-act HIV-1 transmission probability through anal intercourse. “Original estimates” refers to studies included in either previous review^{4, 5}.